Ipsen S.A (I7G) - Net Assets
Based on the latest financial reports, Ipsen S.A (I7G) has net assets worth €4.23 Billion EUR as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€6.83 Billion) and total liabilities (€2.60 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.23 Billion |
| % of Total Assets | 61.93% |
| Annual Growth Rate | 14.17% |
| 5-Year Change | 97.09% |
| 10-Year Change | 241.2% |
| Growth Volatility | 8.49 |
Ipsen S.A - Net Assets Trend (2013–2024)
This chart illustrates how Ipsen S.A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ipsen S.A (2013–2024)
The table below shows the annual net assets of Ipsen S.A from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €4.18 Billion | +9.36% |
| 2023-12-31 | €3.82 Billion | +14.60% |
| 2022-12-31 | €3.34 Billion | +21.16% |
| 2021-12-31 | €2.75 Billion | +29.80% |
| 2020-12-31 | €2.12 Billion | +21.04% |
| 2019-12-31 | €1.75 Billion | -4.90% |
| 2018-12-31 | €1.84 Billion | +20.02% |
| 2017-12-31 | €1.54 Billion | +12.75% |
| 2016-12-31 | €1.36 Billion | +11.15% |
| 2015-12-31 | €1.23 Billion | +14.77% |
| 2014-12-31 | €1.07 Billion | +9.67% |
| 2013-12-31 | €973.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ipsen S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 126.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €345.90 Million | 8.27% |
| Other Components | €3.84 Billion | 91.73% |
| Total Equity | €4.18 Billion | 100.00% |
Ipsen S.A Competitors by Market Cap
The table below lists competitors of Ipsen S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Scentre Group
AU:SCG
|
$13.05 Billion |
|
CNA Financial Corporation
NYSE:CNA
|
$13.05 Billion |
|
First Financial Holding Co Ltd
TW:2892
|
$13.05 Billion |
|
Neste Oyj
F:NEF
|
$13.06 Billion |
|
Penumbra Inc
NYSE:PEN
|
$13.03 Billion |
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
$13.03 Billion |
|
Impala Platinum Holdings Ltd
JSE:IMP
|
$13.02 Billion |
|
Sterling Construction Company Inc
NASDAQ:STRL
|
$12.99 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ipsen S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,825,100,000 to 4,181,600,000, a change of 356,500,000 (9.3%).
- Net income of 345,900,000 contributed positively to equity growth.
- Dividend payments of 99,600,000 reduced retained earnings.
- Share repurchases of 36,500,000 reduced equity.
- Other factors increased equity by 146,700,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €345.90 Million | +8.27% |
| Dividends Paid | €99.60 Million | -2.38% |
| Share Repurchases | €36.50 Million | -0.87% |
| Other Changes | €146.70 Million | +3.51% |
| Total Change | €- | 9.32% |
Book Value vs Market Value Analysis
This analysis compares Ipsen S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.22x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 8.81x to 3.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €18.47 | €162.80 | x |
| 2018-12-31 | €22.16 | €162.80 | x |
| 2019-12-31 | €21.09 | €162.80 | x |
| 2020-12-31 | €25.62 | €162.80 | x |
| 2021-12-31 | €33.35 | €162.80 | x |
| 2022-12-31 | €40.38 | €162.80 | x |
| 2023-12-31 | €46.25 | €162.80 | x |
| 2024-12-31 | €50.56 | €162.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ipsen S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.27%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.68%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.54x
- Recent ROE (8.27%) is below the historical average (16.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 15.70% | 11.90% | 0.82x | 1.61x | €55.35 Million |
| 2014 | 14.41% | 11.52% | 0.78x | 1.61x | €46.98 Million |
| 2015 | 15.53% | 12.49% | 0.78x | 1.59x | €67.65 Million |
| 2016 | 16.62% | 13.52% | 0.69x | 1.78x | €90.01 Million |
| 2017 | 17.85% | 13.54% | 0.65x | 2.01x | €119.76 Million |
| 2018 | 21.16% | 16.59% | 0.70x | 1.83x | €205.39 Million |
| 2019 | -2.90% | -1.88% | 0.63x | 2.46x | €-225.80 Million |
| 2020 | 25.86% | 20.40% | 0.62x | 2.04x | €336.09 Million |
| 2021 | 23.50% | 21.56% | 0.60x | 1.82x | €371.45 Million |
| 2022 | 19.43% | 20.55% | 0.56x | 1.68x | €314.87 Million |
| 2023 | 16.85% | 19.49% | 0.52x | 1.65x | €261.89 Million |
| 2024 | 8.27% | 9.68% | 0.56x | 1.54x | €-72.26 Million |
Industry Comparison
This section compares Ipsen S.A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $870,348,650
- Average return on equity (ROE) among peers: -117.72%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ipsen S.A (I7G) | €4.23 Billion | 15.70% | 0.61x | $13.04 Billion |
| Blueberries Medical Corp (1OA) | $-70.38K | 0.00% | 0.00x | $1.16 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $128.79 Million |
| 27N0 (27N0) | $2.39 Million | -414.95% | 0.12x | $566.23K |
| iAnthus Capital Holdings Inc (2IA) | $17.51 Million | -28.88% | 0.14x | $4.08 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $7.85 Billion | 28.40% | 0.37x | $635.99 Million |
| Revive Therapeutics Ltd (31R) | $821.12K | -218.10% | 0.36x | $397.77K |
| AYR WELLNESS INC.RES.VTG. (3KJB) | $835.32 Million | -29.39% | 1.12x | $5.84 Million |
| Vibe Growth Corporation (3ST) | $-5.22 Million | 0.00% | 0.00x | $214.59K |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $-2.95 Million | 0.00% | 0.00x | $113.81K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
About Ipsen S.A
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more